Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt Wuthrich

Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt Wuthrich
Bengaluru, India: April 5, 2012

Biocon, Asia's Premier Biotechnology Company today, announced the inauguration of its State of the art Integrated Research and Development Centre, by Noble Laureate Prof Kurt Wuthrich. Biocon Research Center (BRC), is aimed at pursuing world class research on biologics that will address unmet medical needs.

As a Biotechnology Research Centre with multi-disciplinary capabilities in Molecular Biology, Biologics Process Sciences, Formulation Research and Preclinical and Clinical Development, BRC is a First-of-its Kind facility in South-East Asia. The Centre is also equipped with cutting edge instrumentation for extensive molecular and functional characterization of Biologics.

Inaugurating the Centre, Prof Kurt Wuthrich said, "I am quite enthralled with the Biocon Research Centre's capability which is at par with international standards. I will keenly watch the outcome of innovation from this centre as I see a lot of promise in the scientific talent at Biocon. I extend my best wishes to Biocon"

Gracing the occasion were eminent Scientific Leaders like Prof C.N.R.Rao, Honorary President, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCSAR); Prof. P. Balaram, Director Indian Institute of Science (IISc) and Prof. K. Vijayraghavan, Director National Centre for Biological Sciences (NCBS).

Biocon has also dedicated a research wing at BRC, in honor of Prof. C.N.R.Rao which was also unveiled on the occasion.

Commenting on this milestone, Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon Group, said: "We aspire to build a centre of research excellence that will pursue an innovation-led effort to develop advanced yet affordable solutions for several debilitating diseases. It will epitomize Biocon's efforts to galvanize the best talent available both in India and from across the globe, and offer them an intellectually stimulating environment combined with an enabling ecosystem to conduct path breaking research for biopharmaceuticals."

Biocon as an emerging global biopharmaceutical enterprise is focused on innovation to develop affordable products and services for patients, partners and healthcare systems across the world. BRC will enable the company to deliver its promise of affordable innovation.

Expressing his delight at the development, Dr Abhijit Barve, President Research and Development, Biocon, said, "This world class facility in India is a dream come true for any scientist and demonstrates Biocon's commitment to world class research. This will allow cross pollination of ideas across groups that will breed a new culture of innovation and enable us to deliver on our Vision."

A team of over 300 scientists based at BRC housed in Biocon Park, will be engaged in cutting edge Biologics research. The Company aims to attract outstanding scientists from the best institutes around the world and engage with international thought leaders as well as participate in technical programs as an effective way to enable innovation through knowledge sharing. An independent quality group at BRC will ensure compliance to Good Laboratory Practices and International regulatory guidelines for developing 'best in class' biologics and biosimilars.

Biocon Research Centre spread across 200,000 sq ft will house the following:

1. Molecular Biology Lab
2. Biologics Process Science Labs
3. Formulations Development Lab
4. Molecular Characterization Lab
5. Functional Bioassay Lab
6.Preclinical and Clinical Development Groups

About Biocon Limited

Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology Company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon's value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. Biocon's robust product offering includes the world's first Pichia-based recombinant Human Insulin, INSUGEN(R) and India's first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) www.biocon.com

Media Relations
Seema Ahuja
Head- Corporate Communications
Biocon Limited
Tel: +91 80 2808 2808
Fax: +9180 2852 3423
Email: [email protected]

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.